• Burkitts Lymphoma - A TMH experience at XXXVI Annual Conference of ISHBT (Indian Society of Haematology and Blood Transfusion) 1995, Bangalore.
  • CNS directed chemotherapy in children less than or equal to 3 years of age: Use of G-CSF in maintaining dose intensity- in Feb 1997 at Madurai in ISMPO (Indian Society of Medical and Paediatric Oncology).
  • Low incidence of cardio toxicity following daunomycin and doxorubicin at a 10 year follow-up in March 1997 at Annual Conference of Bombay Haematology group at Bombay
  • Single centre evaluation of long term follow up of autologous stem cell transplantation for first remission adult ALL: potential for cure without excessive toxicity; Annual meeting of European Bone Marrow Transplantation (EBMT) Group, Innsbruck 6th March 2000.
  • Central nervous system relapse after stem cell transplantation (SCT) for acute leukaemia beyond first remission; Annual meeting of EBMT Group, Innsbruck 6th March 2000.
  • CNS relapse after auto- and allo- stem cell transplant (SCT) for acute leukaemia beyond first CR. 5th Annual Meeting of the European Haematology Association, June 2000.
  • High-dose mephalan with auto-transplantation in Myeloma patients with severe renal dysfunction (GFR <20 ML/MIN/Ms): High incidence of atrial fibrillation and treatment related mortality. 6th Congress of European Haematology Association (EHA) Frankfurt, 24 June 2001
  • Second high-dose melphalan autografts for myeloma patients relapsing after one autograft: results equivalent to tandem transplantation. 28th EBMT Annual Meeting, Montreux, Switzerland, 25th March 2002
  • Bone marrow or peripheral blood stem cell auto transplantation (PBSCT) for acute myeloid leukaemia in first remission? A matched-pair analysis from the Royal Marsden Hospital and the European Blood and Marrow Transplant group (EBMT). 28th EBMT Annual Meeting, Montreux, Switzerland. 27th March 2002
  • Salvage autografts for myeloma patients relapsing after one autograft: results equivalent to tandem transplantation. Annual Scientific Meeting of the British Society for Haematology, Brighton, UK. 16th April 2002.
  • Single centre results of 200mg/m2 melphalan (HDM200) and autograft (tx) in 451 myeloma patients: identifying patients with prolonged survival based upon albumin and 2Microglobulin at transplant at American society of clinical Oncology, Orlando, 20th May 2002
  • Outcome of auto transplantation in 118 adult acute myeloid leukaemia patients in first complete remission: impact of consolidation chemotherapy: 7th Congress of European Haematology Association (EHA), Florence, and Itlay.9th June 2002.
  • High-dose melphalan and second autografts for myeloma relapsing after one autograft: results equivalent to tandem auto transplantation. 7th Congress of EHA, Florence, Italy, 7th June 2002.
  • Long-Term Outcome of Myeloma Patients Treated with an Elective Single Autograft with Follow-up (5 Years): Results Comparable to Tandem Auto transplantation, American society of Haematology, Philadelphia, and 9th Dec 2002.
  • Prognostic Factors at the Time of Single Auto transplantation in 451 Myeloma Patients treated with 200 mg/m2 Melphalan: Results Equivalent to Tandem Auto transplantation, American society of Haematology, Philadelphia, and 9th December 2002.
  • Auto transplantation in Myeloma: Prognostic factors, 29th EBMT Annual Meeting, Istanbul, Turkey, 21st July 2003
  • Prognostic factors at the time of auto transplantation in myeloma, 8th Congress of EHA, Lyons, France 14th June 2003
  • Results of randomised, cross over study comparing pegylated interferon with interferon-alpha2b in patients with myeloma, 8th Congress of EHA, Lyons, France 15th June 2003
  • Serum free light chain assessment in myeloma patients in complete remission, 29th EBMT Annual Meeting, Istanbul, Turkey, 21st July 2003
  • Randomised, two-period cross over study comparing quality of life and toxicity of pegylated interferon with interferon-alpha2b in patients with myeloma, 29th EBMT Annual Meeting, Istanbul, Turkey, 22nd July 2003.
  • Effect of human growth hormone in haemato-oncology patients receiving intensive chemotherapy- a double blind randomised placebo controlled trial, 23rd joint meeting of British Endocrine societies, Brighton, 23rd March 2004.
  • Long term use of Capecitabine in patients with locally recurrent or metastatic breast cancer: concept for metronomic chemotherapy, ESMO Lugano 2008